Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8
The experimentally established mechanism targets of Pregabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 2/20 | 0.63 |
| ▸ | CACNB3 known ✓ | P54284 | 1/20 | 0.63 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.63 |
| ▸ | CACNA2D2 known ✓ | Q9NY47 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.51 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pregabalin SCHEMBL3672687 | 0.83 | CACNA2D1 (0.73) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL26698 | 0.80 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL3668928 | 0.80 | CACNA2D1 (0.63) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL27754092 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL1561104 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL263450 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL15497 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL2370227 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Pregabalin SCHEMBL8227 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Mandelic Acid SCHEMBL28881952 | 0.79 | LMNA (0.62) | LMNAMAPK1GABBR2GABBR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008062460-A2 | CRYSTALLINE FORMS OF PREGABALIN | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| US-20240000727-A1 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2024-01-04 | — | — | US | disclosed |
| EP-4230199-A1 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | Laboratorios Silanes, S.A. de C.V. (MX) | 2023-08-23 | — | — | EP | disclosed |
| US-20200222544-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20180280518-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | AQUESTIVE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20170360942-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MONOSOL RX, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-3229778-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MonoSol Rx LLC (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094567-A1 | LINEAR POLYSACCHARIDE BASED FILM PRODUCTS | MONOSOL RX, LLC (US) | 2016-06-16 | — | — | WO | disclosed |
| EP-2242737-A1 | PREGABALIN SALTS | Synthon B.V. (NL) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009080365-A1 | PREGABALIN SALTS | SYNTHON B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| US-20090170945-A1 | PREGABALIN SALTS | SYNTHON BV (NL) | 2009-07-02 | — | — | US | disclosed |
| WO-2008062460-A2 | CRYSTALLINE FORMS OF PREGABALIN | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| US-20060270871-A1 | POLYMORPHIC FORM I OF PREGABALIN AND PROCESSES FOR ITS PREPARATION | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170945-A1 | PREGABALIN SALTS | GABRG2, SLC6A13, GABRG1 | CACNA2D1 136/4885CACNB3 116/4885CACNA1C 96/4885 |
| US-20240000727-A1 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | OPRD1, TRPV1, OPRK1 | CACNA2D1 185/4885CACNB3 116/4885CACNA1C 26/4885 |
| US-20060270871-A1 | POLYMORPHIC FORM I OF PREGABALIN AND PROCESSES FOR ITS PREPARATION | GABRP, GABRB1, GABRB2 | CACNA2D1 108/4885CACNB3 35/4885CACNA1C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.